Compare Icl Group Ltd (ICL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Incyte Corporation — how do they compare? Icl Group Ltd trades at $5.48 (market cap $6.94B), while Incyte Corporation trades at $120.65 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.5× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.86% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ICL | INCY | |
|---|---|---|
Market Cap | $6.94B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $129.93 |
52-Week Low | $4.80 | $81.61 |
Enterprise Value | $9.58B | $20.04B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.455, up 2.15% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.12 per share, beating estimates, and announced a cost-transformation program. Revenue for 2025 was $7.15 billion, with a net income margin of 3.95%. The stock has a P/E ratio of 22.25 and an EV/EBITDA of 7.02.
Outlook is mixed; earnings beats and operational improvements support upside, but analyst consensus is entirely Hold, reflecting valuation concerns. Key risks include raw material cost volatility and foreign exchange headwinds. The stock offers a dividend yield but faces margin pressure from declining profitability trends.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
